TY - JOUR
T1 - Development of Sarcopenia in Patients With Bladder Cancer
T2 - A Systematic Review
AU - Hansen, Tobias Tuse Dunk
AU - Omland, Lise Høj
AU - von Heymann, Annika
AU - Johansen, Christoffer
AU - Clausen, Mikkel Bek
AU - Suetta, Charlotte
AU - Pappot, Helle
AU - Rafn, Bolette Skjødt
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/2
Y1 - 2021/2
N2 - Objective: Sarcopenia is known to influence cancer-related complications and overall survival. However, the effect of cancer treatment on the development or progression of sarcopenia is relatively unknown. The primary aim of this systematic review was to determine the prevalence and development of sarcopenia among people with bladder cancer. Data Sources: A systematic search was performed in PubMed, Web of Science, and EMBASE. Studies with ≥2 assessments of sarcopenia were eligible for inclusion. Five retrospective cohorts were included with a total of 438 participants. The baseline prevalence of sarcopenia across studies varied from 25% to 69% and post-treatment prevalence from 50% to 81%. The average loss of muscle mass was 2.2% to 10% during a time course of 3 to 12 months. Conclusion: The prevalence of sarcopenia markedly increased during cancer treatment in patients with bladder cancer. Further research into the effect of different treatment regimens on the development of sarcopenia, and how these changes might affect functional capacity and survival is needed. Implications for Nursing Practice: The development of sarcopenia is important to understand because of its negative affect on quality of life, complications, and mortality. Further, understanding how sarcopenia develops during treatment could potentially strengthen nurses’ future care plans for patients with bladder cancer.
AB - Objective: Sarcopenia is known to influence cancer-related complications and overall survival. However, the effect of cancer treatment on the development or progression of sarcopenia is relatively unknown. The primary aim of this systematic review was to determine the prevalence and development of sarcopenia among people with bladder cancer. Data Sources: A systematic search was performed in PubMed, Web of Science, and EMBASE. Studies with ≥2 assessments of sarcopenia were eligible for inclusion. Five retrospective cohorts were included with a total of 438 participants. The baseline prevalence of sarcopenia across studies varied from 25% to 69% and post-treatment prevalence from 50% to 81%. The average loss of muscle mass was 2.2% to 10% during a time course of 3 to 12 months. Conclusion: The prevalence of sarcopenia markedly increased during cancer treatment in patients with bladder cancer. Further research into the effect of different treatment regimens on the development of sarcopenia, and how these changes might affect functional capacity and survival is needed. Implications for Nursing Practice: The development of sarcopenia is important to understand because of its negative affect on quality of life, complications, and mortality. Further, understanding how sarcopenia develops during treatment could potentially strengthen nurses’ future care plans for patients with bladder cancer.
UR - http://www.scopus.com/inward/record.url?scp=85099154672&partnerID=8YFLogxK
U2 - 10.1016/j.soncn.2020.151108
DO - 10.1016/j.soncn.2020.151108
M3 - Review article
C2 - 33431235
AN - SCOPUS:85099154672
SN - 0749-2081
VL - 37
JO - Seminars in Oncology Nursing
JF - Seminars in Oncology Nursing
IS - 1
M1 - 151108
ER -